Cerenome completes enrollment in Phase 2 glioblastoma radiotherapeutic trial
Cerenome, Inc. finished enrolling patients in its Phase 2 ReSPECT‑GBM study of the investigational radiotherapeutic REYOBIQ for recurrent glioblastoma. The trial treated 32 patients at the recommended dose of 22.3 mCi in 8.8 mL, slightly below the original target of 34. Interim data from the first 15 patients showed a median overall survival of 13 months versus about 8 months for historical bevacizumab monotherapy. The company plans to release topline results in mid‑2027 and hold an End‑of‑Phase 2 meeting with the FDA.
Why it matters
The completed enrollment allows the study to proceed to final analysis, and the mid‑2027 topline readout will be a key catalyst for the stock. The company says the 32‑patient cohort is sufficient to maintain statistical power, so investors can expect the data to be robust.
Key facts
- 1Enrollment in the Phase 2 ReSPECT‑GBM trial was completed with 32 patients treated at the recommended dose. investing.com
- 2The recommended Phase 2 dose is 22.3 mCi in 8.8 mL. stocktitan.net
- 3Interim data from the first 15 patients showed a median overall survival of 13 months, compared with approximately 8 months historically for bevacizumab monotherapy. investing.com
- 4Topline data are expected in mid‑2027, followed by an End‑of‑Phase 2 meeting with the FDA. stocktitan.net
- 5The trial is supported by a National Cancer Institute award. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.